

# Huilai Zhang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6490912/publications.pdf>

Version: 2024-02-01

94  
papers

2,058  
citations

331670

21  
h-index

276875

41  
g-index

96  
all docs

96  
docs citations

96  
times ranked

2803  
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved method to stratify lymphoma patients with risk of secondary central nervous system involvement: A multicenter retrospective analysis. <i>Hematological Oncology</i> , 2023, 41, 239-247.	1.7	0
2	Efficacy and safety of GLS-010 (zimberelimab) in patients with relapsed or refractory classical Hodgkin lymphoma: A multicenter, single-arm, phase II study. <i>European Journal of Cancer</i> , 2022, 164, 117-126.	2.8	27
3	Tracking the evolution of untreated high-intermediate/high-risk diffuse large B-cell lymphoma by circulating tumour DNA. <i>British Journal of Haematology</i> , 2022, 196, 617-628.	2.5	7
4	Zanubrutinib monotherapy for relapsed or refractory non-germinal center diffuse large B-cell lymphoma. <i>Blood Advances</i> , 2022, 6, 1629-1636.	5.2	20
5	Comprehensive analysis of TP53 mutation characteristics and identification of patients with inferior prognosis and enhanced immune escape in diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2022, 97, .	4.1	1
6	Tislelizumab for Relapsed/Refractory Classical Hodgkin Lymphoma: 3-Year Follow-up and Correlative Biomarker Analysis. <i>Clinical Cancer Research</i> , 2022, 28, 1147-1156.	7.0	23
7	Pan-Cancer Analysis Reveals Genomic and Clinical Characteristics of TRPV Channel-Related Genes. <i>Frontiers in Oncology</i> , 2022, 12, 813100.	2.8	13
8	Hybrid Membrane Nanovaccines Combined with Immune Checkpoint Blockade to Enhance Cancer Immunotherapy. <i>International Journal of Nanomedicine</i> , 2022, Volume 17, 73-89.	6.7	13
9	Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. <i>Blood</i> , 2022, 139, 3148-3158.	1.4	43
10	Chidamide plus prednisone, etoposide, and thalidomide for untreated angioimmunoblastic T-cell lymphoma in a Chinese population: A multicenter phase II trial. <i>American Journal of Hematology</i> , 2022, 97, 623-629.	4.1	15
11	A novel clinical immune-related prognostic model predicts the overall survival of mantle cell lymphoma. <i>Hematological Oncology</i> , 2022, 40, 343-355.	1.7	2
12	Genetic characteristics involving the PD-1/PD-L1/L2 and CD73/A2aR axes and the immunosuppressive microenvironment in DLBCL. , 2022, 10, e004114.		16
13	PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B-cell lymphoma. <i>Clinical and Translational Medicine</i> , 2022, 12, e808.	4.0	7
14	Distinct clinical and genetic features of hepatitis B virus-associated follicular lymphoma in Chinese patients. <i>Blood Advances</i> , 2022, 6, 2731-2744.	5.2	8
15	Screening of Adverse Prognostic Factors and Construction of Prognostic Index in Previously Untreated Concurrent Follicular Lymphoma and Diffuse Large B-Cell Lymphoma. <i>BioMed Research International</i> , 2022, 2022, 1-18.	1.9	1
16	Phase I study of the anti-BTLA antibody icatolimab as a single agent or in combination with toripalimab in relapsed/refractory lymphomas.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7578-7578.	1.6	5
17	The combination of chidamide with the CHOEP regimen in previously untreated patients with peripheral T-cell lymphoma: a prospective, multicenter, single arm, phase 1b/2 study. <i>Cancer Biology and Medicine</i> , 2021, 18, 841-848.	3.0	15
18	Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open-label phase 2 study (Gxplore-002). <i>Journal of Hematology and Oncology</i> , 2021, 14, 12.	17.0	40

#	ARTICLE	IF	CITATIONS
19	SET-NUP214 Fusion Gene Involved Early T-Cell Precursor Acute Lymphoblastic Leukemia in Adult with B Marker Expression. <i>International Journal of General Medicine</i> , 2021, Volume 14, 659-664.	1.8	5
20	Cancer Cell Membrane Camouflaged Mesoporous Silica Nanoparticles Combined with Immune Checkpoint Blockade for Regulating Tumor Microenvironment and Enhancing Antitumor Therapy. <i>International Journal of Nanomedicine</i> , 2021, Volume 16, 2107-2121.	6.7	30
21	Reduced radiotherapy clinical benefit for primary Waldenstrom's macroglobulinemia in the rituximab era. <i>Hematological Oncology</i> , 2021, 39, 490-497.	1.7	2
22	Comprehensive analysis of peripheral T-cell and natural killer/T-cell lymphoma in Asian patients: A multinational, multicenter, prospective registry study in Asia. <i>The Lancet Regional Health - Western Pacific</i> , 2021, 10, 100126.	2.9	30
23	Tislelizumab (BGB-A317) for relapsed/refractory (R/R) classical Hodgkin lymphoma (cHL): Long-term follow-up efficacy and safety results from a phase 2 study. <i>Journal of Clinical Oncology</i> , 2021, 39, e19507-e19507.	1.6	1
24	Biomimetic black phosphorus quantum dots-based photothermal therapy combined with anti-PD-L1 treatment inhibits recurrence and metastasis in triple-negative breast cancer. <i>Journal of Nanobiotechnology</i> , 2021, 19, 181.	9.1	40
25	Cutaneous T-cell lymphoma in Asian patients: a multinational, multicenter, prospective registry study in Asia. <i>International Journal of Hematology</i> , 2021, 114, 355-362.	1.6	1
26	An Immune-Clinical Prognostic Index (ICPI) for Patients With De Novo Follicular Lymphoma Treated With R-CHOP/CHOP Chemotherapy. <i>Frontiers in Oncology</i> , 2021, 11, 708784.	2.8	3
27	Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK. <i>Aging</i> , 2021, 13, 21102-21121.	3.1	3
28	Programmed Cell Death Protein 1/Programmed Cell Death Ligand-1 Axis activates Intracellular ERK Signaling in Tumor Cells to Mediate Poor Prognosis in T-cell Lymphoma. <i>Journal of Cancer</i> , 2021, 12, 6126-6134.	2.5	1
29	Genome-wide mutational signatures revealed distinct developmental paths for human B cell lymphomas. <i>Journal of Experimental Medicine</i> , 2021, 218, .	8.5	29
30	A novel prognostic signature based on immune-related genes of diffuse large B-cell lymphoma. <i>Aging</i> , 2021, 13, 22947-22962.	3.1	6
31	Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. <i>Journal of Hematology and Oncology</i> , 2021, 14, 167.	17.0	21
32	A Multi-Center, Real-World Study of Chidamide for Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas in China. <i>Frontiers in Oncology</i> , 2021, 11, 750323.	2.8	12
33	Comprehensive Analysis of TP53 Mutation Characteristics and Identification of Patients with Inferior Prognosis and Enhanced Immune Escape in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2021, 138, 4485-4485.	1.4	0
34	m6A Modification Patterns Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment. <i>Blood</i> , 2021, 138, 4486-4486.	1.4	0
35	Biological and Clinical Significance of PIM1 Genetic Alterations in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021, 138, 3494-3494.	1.4	0
36	XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL): Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial). <i>Blood</i> , 2021, 138, 2452-2452.	1.4	1

#	ARTICLE	IF	CITATIONS
37	APR-246 Reveals a Therapeutic Potential Via Triggering Different Cell Death Mechanisms in Diffuse Large B Cell Lymphoma. <i>Blood</i> , 2021, 138, 3521-3521.	1.4	1
38	Chidamide combined with cyclophosphamide, doxorubicin, vincristine and prednisone in previously untreated patients with peripheral T-cell lymphoma. <i>Chinese Journal of Cancer Research: Official Journal of China Anti-Cancer Association</i> , Beijing Institute for Cancer Research, 2021, 33, 616-626.	2.2	10
39	Treatment of relapsed or refractory classical Hodgkin lymphoma with the anti-PD-1, tislelizumab: results of a phase 2, single-arm, multicenter study. <i>Leukemia</i> , 2020, 34, 533-542.	7.2	104
40	Tumor-derived CK1 $\pm$ mutations enhance MDMX inhibition of p53. <i>Oncogene</i> , 2020, 39, 176-186.	5.9	8
41	Genetic Mutations of Tim-3 Ligand and Exhausted Tim-3+ CD8+ T Cells and Survival in Diffuse Large B Cell Lymphoma. <i>Journal of Immunology Research</i> , 2020, 2020, 1-9.	2.2	12
42	Plasma soluble PD-L1 and STAT3 predict the prognosis in diffuse large B cell lymphoma patients. <i>Journal of Cancer</i> , 2020, 11, 7001-7008.	2.5	17
43	Electrocardiographic characteristics of diffuse large B-cell lymphoma patients treated with anthracycline-based chemotherapy. <i>Journal of Electrocardiology</i> , 2020, 60, 195-199.	0.9	9
44	Combination immunotherapy of oncolytic virus nanovesicles and PD-1 blockade effectively enhances therapeutic effects and boosts antitumour immune response. <i>Journal of Drug Targeting</i> , 2020, 28, 982-990.	4.4	4
45	Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. <i>Clinical Cancer Research</i> , 2020, 26, 4216-4224.	7.0	126
46	Combination of baseline total metabolic tumor volume measured on FDG-PET / CT and $\beta_2$ -microglobulin have a robust predictive value in patients with primary breast lymphoma. <i>Hematological Oncology</i> , 2020, 38, 493-500.	1.7	3
47	Apatinib Inhibits Cell Proliferation and Induces Autophagy in Human Papillary Thyroid Carcinoma via the PI3K/Akt/mTOR Signaling Pathway. <i>Frontiers in Oncology</i> , 2020, 10, 217.	2.8	36
48	Long-Term Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study. <i>Blood</i> , 2020, 136, 1-1.	1.4	13
49	miR-150 is a negative independent prognostic biomarker for primary gastrointestinal diffuse large B cell lymphoma. <i>Oncology Letters</i> , 2020, 19, 3487-3494.	1.8	5
50	Overexpression of microRNA-130a predicts adverse prognosis of primary gastrointestinal diffuse large B cell lymphoma. <i>Oncology Letters</i> , 2020, 20, 1-1.	1.8	3
51	Gls-010, a Novel Anti-PD-1 Mab in Chinese Patients with Relapsed or Refractory Classical Hodgkin Lymphoma: Preliminary Impressive Results of a Phase II Clinical Trial. <i>Blood</i> , 2020, 136, 17-17.	1.4	0
52	Tumor Microenvironment Associated with Complete Response to Tislelizumab Monotherapy in Relapsed/Refractory Classical Hodgkin Lymphoma Reveals a Potentially Different Mechanism of Action. <i>Blood</i> , 2020, 136, 17-17.	1.4	1
53	Clinical significance of enhancer of zeste homolog 2 and histone deacetylases 1 and 2 expression in peripheral T cell lymphoma. <i>Oncology Letters</i> , 2019, 18, 1415-1423.	1.8	11
54	CD5 expression correlates with inferior survival and enhances the negative effect of p53 overexpression in diffuse large B cell lymphoma. <i>Hematological Oncology</i> , 2019, 37, 360-367.	1.7	21

#	ARTICLE	IF	CITATIONS
55	Tumor CD73/A2aR adenosine immunosuppressive axis and tumor-infiltrating lymphocytes in diffuse large B-cell lymphoma: correlations with clinicopathological characteristics and clinical outcome. <i>International Journal of Cancer</i> , 2019, 145, 1414-1422.	5.1	24
56	Plasma soluble programmed death ligand 1 levels predict clinical response in peripheral T-cell lymphomas. <i>Hematological Oncology</i> , 2019, 37, 270-276.	1.7	18
57	Association of Cancer and the Risk of Developing Atrial Fibrillation: A Systematic Review and Meta-Analysis. <i>Cardiology Research and Practice</i> , 2019, 2019, 1-9.	1.1	34
58	Pralatrexate in Chinese Patients with Relapsed or Refractory Peripheral T-cell Lymphoma: A Single-arm, Multicenter Study. <i>Targeted Oncology</i> , 2019, 14, 149-158.	3.6	14
59	AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent Lymphoma. <i>Journal of Clinical Oncology</i> , 2019, 37, 1188-1199.	1.6	277
60	Safety and Efficacy of Orelabrutinib Monotherapy in Chinese Patients with Relapsed or Refractory Mantle Cell Lymphoma: A Multicenter, Open-Label, Phase II Study. <i>Blood</i> , 2019, 134, 755-755.	1.4	21
61	Efficacy and time to next treatment following lenalidomide/rituximab ( $R^{2}$ ) or rituximab/placebo in patients with R/R indolent NHL (AUGMENT).. <i>Journal of Clinical Oncology</i> , 2019, 37, 7514-7514.	1.6	0
62	Plasma Soluble Programmed Death Ligand 1 Levels Predict Clinical Response in Peripheral T-Cell Lymphomas. <i>Blood</i> , 2019, 134, 5231-5231.	1.4	0
63	Evaluation of the Prognostic Significance and Effect of NT5E-Adenosine Axis, a Novel Immune Checkpoint, in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 2801-2801.	1.4	0
64	SNF5 deficiency induces apoptosis resistance by repressing SATB1 expression in S�zary syndrome. <i>Leukemia and Lymphoma</i> , 2018, 59, 2405-2413.	1.3	6
65	Genetic landscape of hepatitis B virus-associated diffuse large B-cell lymphoma. <i>Blood</i> , 2018, 131, 2670-2681.	1.4	77
66	Characteristics and outcomes of non-Hodgkin's lymphoma patients with leptomeningeal metastases. <i>International Journal of Clinical Oncology</i> , 2018, 23, 783-789.	2.2	6
67	Primary breast diffuse large B-cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure. <i>Cancer Science</i> , 2018, 109, 3943-3952.	3.9	26
68	Prognostic Significance of BCL-2 and BCL-6 Expression in MYC-positive DLBCL. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e381-e389.	0.4	14
69	Immunochemotherapeutic increase of peripheral absolute monocyte count predicts interstitial pneumonia in lymphoma patients. <i>Hematological Oncology</i> , 2018, 36, 779-785.	1.7	3
70	TPGS functionalized mesoporous silica nanoparticles for anticancer drug delivery to overcome multidrug resistance. <i>Materials Science and Engineering C</i> , 2018, 84, 108-117.	7.3	38
71	AUGMENT: A Phase III Randomized Study of Lenalidomide Plus Rituximab (R2) Vs Rituximab/Placebo in Patients with Relapsed/Refractory Indolent Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 445-445.	1.4	9
72	Baseline Characteristics of 3046 Non-Hodgkin's Lymphoma Patients Diagnosed between July 2015 and May 2018: A Report from China Lymphoma Patient Registry (CLAP). <i>Blood</i> , 2018, 132, 5394-5394.	1.4	2

#	ARTICLE	IF	CITATIONS
73	Baseline Characteristics of 412 Hodgkin's Lymphoma Patients Diagnosed between July 2015 and May 2018: A Report from China Lymphoma Patient Registry (CLAP). <i>Blood</i> , 2018, 132, 5362-5362.	1.4	0
74	Pattern of Rituximab Use Among Patients with B-Cell Non-Hodgkin's Lymphoma: A Report from China Lymphoma Patient Registry (CLAP). <i>Blood</i> , 2018, 132, 5419-5419.	1.4	0
75	Inhibition of 4EBP phosphorylation mediates the cytotoxic effect of mechanistic target of rapamycin kinase inhibitors in aggressive B-cell lymphomas. <i>Haematologica</i> , 2017, 102, 755-764.	3.5	24
76	Synergistic antitumor effect of histone deacetylase inhibitor and Doxorubicin in peripheral T-cell lymphoma. <i>Leukemia Research</i> , 2017, 56, 29-35.	0.8	30
77	Identification of potential target genes associated with the effect of propranolol on angiosarcoma via microarray analysis. <i>Oncology Letters</i> , 2017, 13, 4267-4275.	1.8	4
78	Upconverting and persistent luminescent nanocarriers for accurately imaging-guided photothermal therapy. <i>Materials Science and Engineering C</i> , 2017, 79, 191-198.	7.3	16
79	Bioinformatic analysis of the effects and mechanisms of decitabine and cytarabine on acute myeloid leukemia. <i>Molecular Medicine Reports</i> , 2017, 16, 281-287.	2.4	3
80	Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. <i>Journal of Hematology and Oncology</i> , 2017, 10, 69.	17.0	155
81	Identification of target gene of venous thromboembolism in patients with lymphoma via microarray analysis. <i>Oncology Letters</i> , 2017, 14, 3313-3318.	1.8	1
82	Integrated analysis of genome-wide gene expression and DNA methylation microarray of diffuse large B-cell lymphoma with TET mutations. <i>Molecular Medicine Reports</i> , 2017, 16, 3777-3782.	2.4	9
83	MiR-193a-3p is an Important Tumour Suppressor in Lung Cancer and Directly Targets KRAS. <i>Cellular Physiology and Biochemistry</i> , 2017, 44, 1311-1324.	1.6	64
84	Efficacy and safety of triple therapy with aprepitant, ondansetron, and prednisone for preventing nausea and vomiting induced by R-CEOP or CEOP chemotherapy regimen for non-Hodgkin lymphoma: a phase 2 open-label, randomized comparative trial. <i>Leukemia and Lymphoma</i> , 2017, 58, 816-821.	1.3	6
85	Combined Analysis of ChIP Sequencing and Gene Expression Dataset in Breast Cancer. <i>Pathology and Oncology Research</i> , 2017, 23, 361-368.	1.9	14
86	Genetic basis of PD-L1 overexpression in diffuse large B-cell lymphomas. <i>Blood</i> , 2016, 127, 3026-3034.	1.4	168
87	Identification of targets of miRNA-221 and miRNA-222 in fulvestrant-resistant breast cancer. <i>Oncology Letters</i> , 2016, 12, 3882-3888.	1.8	10
88	miR-10a inhibits cell proliferation and promotes cell apoptosis by targeting BCL6 in diffuse large B-cell lymphoma. <i>Protein and Cell</i> , 2016, 7, 899-912.	11.0	45
89	Co-expression of PD-L1 and p-AKT is associated with poor prognosis in diffuse large B-cell lymphoma via PD-1/PD-L1 axis activating intracellular AKT/mTOR pathway in tumor cells. <i>Oncotarget</i> , 2016, 7, 33350-33362.	1.8	56
90	Primary Breast Diffuse Large B Cell Lymphoma in the Rituximab Era: Outcomes of a Multicenter Retrospective Study By the Lymphoma and Leukemia Committee of Chinese Geriatric Oncology Society(LLC-CGOS). <i>Blood</i> , 2016, 128, 4228-4228.	1.4	1

#	ARTICLE	IF	CITATIONS
91	Gemcitabine, Navelbine, and Doxorubicin as Treatment for Patients with Refractory or Relapsed T-Cell Lymphoma. <i>BioMed Research International</i> , 2015, 2015, 1-7.	1.9	3
92	A Phase I Trial to Evaluate the Multiple-Dose Safety and Antitumor Activity of Ursolic Acid Liposomes in Subjects with Advanced Solid Tumors. <i>BioMed Research International</i> , 2015, 2015, 1-7.	1.9	53
93	Microrna-17-92 Cluster Upregulates NF-KB Activity Via Suppressing Multiple NF-KB Negative Regulators Mediating Ubiquitination. <i>Blood</i> , 2015, 126, 3638-3638.	1.4	0
94	Expression of preprotachykinin-I (PPT-I), neurokinin-1 (NK-1) and neurokinin-2 (NK-2) in breast cancer cells improves tumor cell survival in bone marrow in the early stage of metastasis. <i>Clinical Oncology and Cancer Research</i> , 2009, 6, 225-232.	0.1	1